Palbociclib as single agent or in combination with the endocrine therapy received before disease progression for estrogen receptor-positive, HER2-negative metastatic breast cancer: TREnd trial

Malorni, L. ; Curigliano, G. ; Minisini, A.M. ; Cinieri, S. ; Tondini, C.A. ; D’Hollander, K. ; Arpino, G. ; Bernardo, A. ; Martignetti, A. ; Criscitiello, C. ; Puglisi, F. ; Pestrin, M. ; Sanna, G. ; Moretti, E. ; Risi, E. ; Biagioni, C. ; McCartney, A. ; Boni, L. ; Buyse, M. ; Migliaccio, I. ; Biganzoli, L. ; Di Leo, A.

England: Elsevier Ltd

Texto completo disponível

8P Mutational analysis of circulating tumour DNA (ctDNA) in patients with ER+/HER2- advanced breast cancer (ABC) receiving palbociclib (P): Results from the TREnd trial

Malorni, L. ; Romagnoli, D. ; Benelli, M. ; Galardi, F. ; Biagioni, C. ; Curigliano, G. ; Minisini, A.M. ; Moretti, E. ; Risi, E. ; De Luca, F. ; McCartney, A. ; Di Leo, A. ; Biganzoli, L. ; Migliaccio, I.

Texto completo disponível

6P Circulating tumour cells (CTCs) as biomarkers of resistance to the CDK4/6 inhibitor (CDK4/6i) palbociclib (P) in patients (pts) with ER+/HER2-negative advanced breast cancer (ABC)

Galardi, F. ; Biagioni, C. ; De Luca, F. ; Curigliano, G. ; Minisini, A.M. ; Bonechi, M. ; Moretti, E. ; Risi, E. ; Migliaccio, I. ; McCartney, A. ; Benelli, M. ; Romagnoli, D. ; Conti, V. ; Biganzoli, L. ; Di Leo, A. ; Malorni, L.

Elsevier Ltd

Texto completo disponível

Metabolomic analysis as a tool to identify breast cancer (BC) cell lines resistant to palbociclib (PD)

Bonechi, M. ; Guarducci, C. ; Meoni, G. ; Tenori, L. ; Biagioni, C. ; Schiff, R. ; Osborne, C.K. ; Luchinat, C. ; Malorni, L. ; Migliaccio, I.

Texto completo disponível

Gene signatures as potential predictive markers of response to neoadjuvant chemotherapy in ER+/HER2+ breast cancer patients

Risi, E. ; Grilli, A. ; Migliaccio, I. ; Biagioni, C. ; Guarducci, C. ; Bonechi, M. ; McCartney, A. ; Vitale, S. ; Biganzoli, L. ; Bicciato, S. ; Di Leo, A. ; Malorni, L.

Elsevier Ltd

Texto completo disponível

Low hormone receptor (HR) status and the benefit of hormonal therapy (HT) in patients with early breast cancer (EBC)

Guarducci, C. ; Bonechi, M. ; Biagioni, C. ; Malorni, L. ; Biganzoli, L. ; Truglia, M.C. ; Vitale, S. ; Soldi, G. ; Di Leo, A. ; Migliaccio, I.

Elsevier Ltd

Texto completo disponível

AP-2gamma as a novel biomarker of endocrine resistance: Results from the TransCONFIRM study

Malorni, L. ; Biagioni, C. ; Guarducci, C. ; Bonechi, M. ; Capaccioli, G. ; Jeselsohn, R. ; Barry, W.T. ; Laing, N. ; Di Leo, A. ; Migliaccio, I.

Elsevier Ltd

Texto completo disponível

Identification of gene expression signatures of palbociclib (PD) response in breast cancer (BC)

Migliaccio, I. ; Piazza, S. ; Verardo, R. ; Guarducci, C. ; Bonechi, M. ; Ciani, Y. ; Moretti, E. ; Siclari, O. ; Di Leo, A. ; Malorni, L.

Elsevier Ltd

Texto completo disponível

Efficacy of Fulvestrant According to Duration and Type of Adjuvant Endocrine Treatment, in Metastatic Breast Cancer Patients Enrolled in the Confirm Trial

Malorni, L. ; Biagioni, C. ; Thirlwell, J. ; Guarducci, C. ; Bonechi, M. ; Rukazenkov, Y. ; Jerusalem, G. ; Martin, M. ; di Leo, A. ; Migliaccio, I.

Elsevier Ltd

Texto completo disponível

Prognostic Role of Luminal Subtype in Metastatic Breast Cancer Patients Treated with Fulvestrant in the Confirm Trial

Migliaccio, I. ; Biagioni, C. ; Thirlwell, J. ; Galardi, F. ; Guarducci, C. ; Capaccioli, G. ; Truglia, M. ; Rukazenkov, Y. ; di Leo, A. ; Malorni, L.

Elsevier Ltd

Texto completo disponível